UA8037A1 - СПОСІБ ОДЕРЖАННЯ КЛОНА БАКТЕРІЙ ESCHERICHIA COLI, ТРАНСФОРМОВАНОГО ПЛАЗМІДОЙ РBR322, ЯКИЙ МІСТИТЬ ВСТАВКУ Pst-1, КОДУЮЧУ ІНТЕРФЕРОН alРha АБО beta - Google Patents

СПОСІБ ОДЕРЖАННЯ КЛОНА БАКТЕРІЙ ESCHERICHIA COLI, ТРАНСФОРМОВАНОГО ПЛАЗМІДОЙ РBR322, ЯКИЙ МІСТИТЬ ВСТАВКУ Pst-1, КОДУЮЧУ ІНТЕРФЕРОН alРha АБО beta

Info

Publication number
UA8037A1
UA8037A1 UA3598429A UA3598429A UA8037A1 UA 8037 A1 UA8037 A1 UA 8037A1 UA 3598429 A UA3598429 A UA 3598429A UA 3598429 A UA3598429 A UA 3598429A UA 8037 A1 UA8037 A1 UA 8037A1
Authority
UA
Ukraine
Prior art keywords
beta
pst
plasmodium
bacteria
coli transformed
Prior art date
Application number
UA3598429A
Other languages
English (en)
Russian (ru)
Inventor
Дворкін-Растль Ева
Дворкін Марк-Брус
Дворкин Марк-Брус
Адольф Гюнтер
Мейндль Петер
Бодо Герхард
Светли Петер
Original Assignee
"Др.Карл Томе Гмбх"
"Др. Карл Томе Гмбх"
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=6164725&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA8037(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by "Др.Карл Томе Гмбх", "Др. Карл Томе Гмбх" filed Critical "Др.Карл Томе Гмбх"
Publication of UA8037A1 publication Critical patent/UA8037A1/uk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1096—Processes for the isolation, preparation or purification of DNA or RNA cDNA Synthesis; Subtracted cDNA library construction, e.g. RT, RT-PCR
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/14—Lymphokine; related peptides
    • Y10S930/142—Interferon

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Toxicology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Спосіб одержання клону бактерій Escherichia coli, трансформованого плазмідою pBR322, що містить вставку Pst-1, що кодує інтерферон а або , включає одержання фрагментів кДНК, що містять послідовність, що кодує, для генів ,-и --інтерферону, шляхом виділення іРНК із індукованих вірусом Сендай клітин В-лімфоцитів синтезу на матриці пoлі(A)+PHK кДНК за допомогою зворотної транскріптази. З метою одночасного відбору клонів, що несуть рекомбінантні молекули ДНК із геном, що кодує P и -інтерферон, іРНК виділяється із клітин (-лімфоцитів Namalwa після закінчення 9 год після індукції вірусом, а синтез кДНК здійснюється на (А) РНК із величиною молекули 6 і 18 S.
UA3598429A 1982-05-28 1983-05-27 СПОСІБ ОДЕРЖАННЯ КЛОНА БАКТЕРІЙ ESCHERICHIA COLI, ТРАНСФОРМОВАНОГО ПЛАЗМІДОЙ РBR322, ЯКИЙ МІСТИТЬ ВСТАВКУ Pst-1, КОДУЮЧУ ІНТЕРФЕРОН alРha АБО beta UA8037A1 (uk)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19823220116 DE3220116A1 (de) 1982-05-28 1982-05-28 Mikrobiologisch hergestellte (alpha)- und ss-interferone, dna-sequenzen, die fuer diese interferone codieren, mikroorganismen, die diese genetische information enthalten, und verfahren zu ihrer herstellung

Publications (1)

Publication Number Publication Date
UA8037A1 true UA8037A1 (uk) 1995-12-26

Family

ID=6164725

Family Applications (1)

Application Number Title Priority Date Filing Date
UA3598429A UA8037A1 (uk) 1982-05-28 1983-05-27 СПОСІБ ОДЕРЖАННЯ КЛОНА БАКТЕРІЙ ESCHERICHIA COLI, ТРАНСФОРМОВАНОГО ПЛАЗМІДОЙ РBR322, ЯКИЙ МІСТИТЬ ВСТАВКУ Pst-1, КОДУЮЧУ ІНТЕРФЕРОН alРha АБО beta

Country Status (22)

Country Link
US (1) US4820638A (uk)
EP (1) EP0095702B1 (uk)
JP (2) JPH0774238B2 (uk)
KR (1) KR920006349B1 (uk)
AT (1) ATE42114T1 (uk)
AU (1) AU565479B2 (uk)
DD (1) DD211359C4 (uk)
DE (2) DE3220116A1 (uk)
DK (1) DK164742C (uk)
ES (2) ES522762A0 (uk)
FI (1) FI82072C (uk)
GR (1) GR79236B (uk)
HK (1) HK112893A (uk)
HU (1) HU196452B (uk)
IL (1) IL68790A (uk)
MX (1) MX9202815A (uk)
NO (1) NO168538C (uk)
NZ (1) NZ204384A (uk)
SG (1) SG38692G (uk)
SU (1) SU1346048A3 (uk)
UA (1) UA8037A1 (uk)
ZA (1) ZA833845B (uk)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3247922A1 (de) * 1982-12-24 1984-06-28 Boehringer Ingelheim International GmbH, 6507 Ingelheim Dna-sequenzen, deren herstellung, diese sequenzen enthaltende plasmide und deren verwendung zur synthese eukaryotischer genprodukte in prokaryoten
DE3515336C2 (de) * 1985-04-27 1994-01-20 Boehringer Ingelheim Int Verfahren zur Herstellung und Reinigung von â-Interferon
US4709324A (en) * 1985-11-27 1987-11-24 Motorola, Inc. Data processor control unit having an interrupt service using instruction prefetch redirection
CA2025180A1 (en) * 1989-10-12 1991-04-13 William G. Weisburg Nucleic acid probes and methods for detecting pathogenic candida yeasts
US6685933B1 (en) * 1998-07-28 2004-02-03 The United States Of America As Represented By The Department Of Health And Human Services Interferon α hybrids
AU2587002A (en) * 2000-11-03 2002-05-15 Biomedicines Inc Method for short-term and long-term drug dosimetry
FR2817559B1 (fr) * 2000-12-06 2003-12-12 Genodyssee Procede de determination d'un ou plusieurs polymorphisme(s) fontionnel(s) dans la sequence nucleique d'un gene "candidat" fonctionnel preselectionne et ses applications
FR2821625B1 (fr) * 2001-03-01 2003-05-16 Genodyssee Nouveaux polynucleotides comportant un polymorphisme de type snp fonctionnel dans la sequence nucleotidique du gene ifn-alpha-2 ainsi que de nouveaux polypeptides codes par ces polynucleotides et leurs utilisations therapeutiques
FR2823220B1 (fr) * 2001-04-04 2003-12-12 Genodyssee Nouveaux polynucleotides et polypeptides de l'erythropoietine (epo)
EP1536839B1 (en) * 2001-11-09 2010-09-15 Intarcia Therapeutics, Inc Combination therapy comprising omega-interferon for treating infection with hepatitis c virus or yellow fever virus
US20040063912A1 (en) * 2002-03-15 2004-04-01 The Brigham And Women's Hospital, Inc. Central airway administration for systemic delivery of therapeutics
WO2003099320A1 (en) 2002-05-24 2003-12-04 Zensun (Shanghai) Sci-Tech.Ltd Neuregulin based methods and compositions for treating viral myocarditis and dilated cardiomyopathy
DE60332358D1 (de) * 2002-09-09 2010-06-10 Hanall Pharmaceutical Co Ltd Protease-resistente modifizierte interferon alpha polypeptide
NZ548256A (en) 2004-02-02 2010-02-26 Ambrx Inc Modified human four helical bundle polypeptides and their uses
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
AU2007266475B2 (en) 2006-05-30 2009-12-03 Intarcia Therapeutics, Inc. Two-piece, internal-channel osmotic delivery system flow modulator
DK2049081T3 (da) 2006-08-09 2013-02-25 Intarcia Therapeutics Inc Osmotiske leveringssystemer og stempelarrangementer
US20080260820A1 (en) * 2007-04-19 2008-10-23 Gilles Borrelly Oral dosage formulations of protease-resistant polypeptides
PT2157967E (pt) 2007-04-23 2013-04-03 Intarcia Therapeutics Inc Formulações de suspensões de péptidos insulinotrópicos e suas utilizações
DK2240155T3 (da) 2008-02-13 2012-09-17 Intarcia Therapeutics Inc Indretninger, formuleringer og fremgangsmåder til levering af flere gavnlige midler
KR102148624B1 (ko) 2009-09-28 2020-08-26 인타르시아 세라퓨틱스 인코포레이티드 실질 항정상태 약물 전달의 신속 확립 및/또는 종결
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
WO2013024156A2 (en) 2011-08-17 2013-02-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Combinations of anti-hcv-entry factor antibodies and interferons for the treatment and the prevention of hcv infection
WO2013024158A1 (en) 2011-08-17 2013-02-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Combinations of protein kinase inhibitors and interferons or of protein kinase inhibitors and direct acting antivirals for the treatment and the prevention of hcv infection
WO2014033266A1 (en) 2012-08-31 2014-03-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-sr-bi antibodies for the inhibition of hepatitis c virus infection
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
KR20240042548A (ko) 2015-06-03 2024-04-02 인타르시아 세라퓨틱스 인코포레이티드 임플란트 배치 및 제거 시스템들
CN109310743A (zh) 2016-05-16 2019-02-05 因塔西亚制药公司 胰高血糖素受体选择性多肽及其使用方法
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
KR20190104039A (ko) 2017-01-03 2019-09-05 인타르시아 세라퓨틱스 인코포레이티드 Glp-1 수용체 효능제의 연속적인 투여 및 약물의 동시-투여를 포함하는 방법

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2906160A1 (de) * 1979-02-17 1980-09-04 Thomae Gmbh Dr K Verbessertes verfahren zur herstellung von humaninterferon
AU538665B2 (en) * 1979-10-30 1984-08-23 Juridical Foundation, Japanese Foundation For Cancer Research Human interferon dna
IL58765A (en) * 1979-11-21 1986-09-30 Yeda Res & Dev Process for the production of essentially pure messenger rna of human fibroblast interferon and process for the production of interferon beta
US4530901A (en) * 1980-01-08 1985-07-23 Biogen N.V. Recombinant DNA molecules and their use in producing human interferon-like polypeptides
NO164037C (no) * 1980-01-08 1990-08-22 Biogen Inc Fremgangsmaate ved fremstilling av et polypeptid av interferon alfa (ifnalfa)-type.
GB2068970B (en) * 1980-02-06 1983-06-22 Searle & Co Recombinant dna technique for the preparation of a protein resembling human interferon
DE3005843A1 (de) * 1980-02-16 1981-09-10 Hoechst Ag, 6000 Frankfurt Genprodukt eines hoeheren organismus aus einem dieses gen enthaltenden mikroorganismus
DE3005897A1 (de) * 1980-02-16 1981-09-03 Hoechst Ag, 6000 Frankfurt Genprodukt eines hoeheren organismus aus einem dieses gen enhtaltenden mikroorganismus
ES506955A0 (es) * 1980-11-10 1983-02-01 Genentech Inc Un procedimiento para producir un polipeptido antiviral.
DE3106982A1 (de) * 1981-02-25 1982-09-09 Dr. Karl Thomae Gmbh, 7950 Biberach "neues tridecadeoxynukleotid, verfahren zu seiner herstellung und verwendung"
IL63327A (en) * 1981-07-16 1985-11-29 Yeda Res & Dev Production of interferon beta1 and alpha-phage recombinants for its production in host bacteria
GB2108510B (en) * 1981-10-03 1984-12-12 Ciba Geigy Ag Dnas, recombinant dnas, hosts containing them, polypeptides and processes for the production thereof

Also Published As

Publication number Publication date
ZA833845B (en) 1985-01-30
JPH0678774A (ja) 1994-03-22
IL68790A0 (en) 1983-09-30
DK164742C (da) 1992-12-28
FI831818L (fi) 1983-11-29
NO168538B (no) 1991-11-25
FI831818A0 (fi) 1983-05-23
DD211359A5 (de) 1984-07-11
ES8403522A1 (es) 1984-03-16
SG38692G (en) 1992-09-04
IL68790A (en) 1991-06-10
DK239383A (da) 1983-11-29
NZ204384A (en) 1986-11-12
JPS5925689A (ja) 1984-02-09
KR840004944A (ko) 1984-10-31
ES522762A0 (es) 1984-03-16
HU196452B (en) 1988-11-28
JP2558422B2 (ja) 1996-11-27
NO831903L (no) 1983-11-29
HK112893A (en) 1993-10-29
NO168538C (no) 1992-03-04
US4820638A (en) 1989-04-11
ES8500321A1 (es) 1984-10-01
DD211359C4 (de) 1986-09-24
FI82072B (fi) 1990-09-28
DK164742B (da) 1992-08-10
EP0095702B1 (de) 1989-04-12
EP0095702A1 (de) 1983-12-07
DE3379591D1 (en) 1989-05-18
AU1504483A (en) 1983-12-01
ATE42114T1 (de) 1989-04-15
ES529360A0 (es) 1984-10-01
DE3220116A1 (de) 1983-12-01
KR920006349B1 (ko) 1992-08-03
DK239383D0 (da) 1983-05-27
SU1346048A3 (ru) 1987-10-15
GR79236B (uk) 1984-10-22
MX9202815A (es) 1992-06-30
DE3220116C2 (uk) 1993-02-18
AU565479B2 (en) 1987-09-17
FI82072C (fi) 1991-01-10
JPH0774238B2 (ja) 1995-08-09

Similar Documents

Publication Publication Date Title
UA8037A1 (uk) СПОСІБ ОДЕРЖАННЯ КЛОНА БАКТЕРІЙ ESCHERICHIA COLI, ТРАНСФОРМОВАНОГО ПЛАЗМІДОЙ РBR322, ЯКИЙ МІСТИТЬ ВСТАВКУ Pst-1, КОДУЮЧУ ІНТЕРФЕРОН alРha АБО beta
SE8603145D0 (sv) Forfarande for framstellning av interferon-beta
ES8705521A1 (es) Un metodo de producir un polipetido similar a factor de necrosis de tumores (tnf) de mamiferos.
EP0034307A3 (en) Microbiologically produced polypeptide having the amino acid sequence of human interferon, dna and plasmids coding for this sequence, microorganisms containing this genetic information and process for their production
CS9100531A2 (en) Dna fragment that codes polypeptide with nitrile-hydratation activity,transformant that contains this gene and method of amides preparation with this transformant application
EG19101A (en) Process for preparing of expression of human proapolipoprotein A.1.
ES8403969A1 (es) Un metodo para producir polipetido semejante a interferon inmune humano.
ES8302778A1 (es) Un procedimiento para producir un polipeptido antiviral.
ES8308534A1 (es) Un metodo de producir un polipeptido que exhibe actividad inmunologica o biologica del interferon de leucocitos humanos.
DE3276241D1 (en) Expression of polypeptides in yeast
MY102902A (en) Lymphokine production and purification.
KR830005355A (ko) 박테리아숙주내에서 각종 폴리펩타이드를 합성하는 방법 및 폴리펩타이드 dna
HUT52551A (en) Process for production of neutrophil-activizating factor
DK587488D0 (da) Fibroblast-vaekstfaktor, nucleotidsekvens kodende derfor, praeparat indeholdende faktoren og fremgangsmaade til fremstilling deraf
EP0072541A3 (en) Human leukocyte interferons, process for their microbial production, intermediates therefor and compositions containing them
EP0034306A3 (en) Microbiologically produced polypeptide having the amino acid sequence of human interferon, dna and plasmids coding for this sequence, microorganisms containing this genetic information and process for their production
Chinnadurai et al. Dual role of gene D5 in the development of bacteriophage T5
ES8700694A1 (es) Un procedimiento para producir un polipeptido de interferon hibrido antivirico y antiproliferante
ES8603570A1 (es) Un metodo de producir pro-uroquinasa monocatenaria glicosi- lada